Cetuximab after immunotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed head and neck squamous cell cancer based on biopsy or cell testing.
- Your scans show at least one measurable tumor that can be tracked during the study.
- You previously received immunotherapy that targets PD-1 (with or without chemotherapy).
- You’re age 18 or older and can follow the study plan and sign consent.
- Your overall health is good enough (performance status 0–2) as judged by the study team.
- You have not had cetuximab before, and you have not had medicines that directly target the EGFR pathway in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests whether combining an immunotherapy drug (camrelizumab) with another targeted therapy or chemotherapy given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. It aims to see if this approach is more effective than standard treatments.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.